Abstract
Purpose :
To evaluate the efficacy and the safety of a trabecular microbypass stent (iStent) surgery in patients with secondary glaucoma: uveitic glaucoma, post vitrectomy glaucoma, and steroid induced glaucoma.
Methods :
Retrospective case series included eyes with secondary glaucoma which had implantation of 1 stent. Data were collected preoperatively and postoperatively through 9 months. Data included intraocular pressure (IOP), number of glaucoma medications, the incidence of postoperative IOP spikes >15 mm Hg at any timepoint, and the need for additional surgery.
Results :
The series included 9 eyes: 4 uveitic glaucoma, 3 post vitrectomy glaucoma and 2 steroid induced glaucoma. The mean preoperative IOP was 26.33 mm Hg ± 8.72 (SD). Nine months postoperatively, the mean IOP was significantly reduced to 13.44 ± 3.36 mm Hg (P = 0.002). The mean number of glaucoma medications was also decreased from 2.56 ± 1.01 at the baseline visit to 1.78 ± 1.09 at 9 month postoperative visit (P = 0.043). During the postoperative follow up period, 2 eyes (22%) experienced an IOP spike > 15 mm Hg; Whereas 1 eye was well controlled with topical treatment, the other one needed to have Ahmed valve implantation surgery. There were no significant complications during the entire follow up period.
Conclusions :
Trabecular microbypass stent implantation surgery safely and effectively lowered IOP and glaucoma medication use in patients with secondary glaucoma.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.